PHARMA SIGNALOPEN RESEARCH PLATFORM →
EMASafety / PharmacovigilancePLATFORM PUBLISHED 2026-07-10

PRAC meeting highlights 6–9 July 2026

PRAC agreed direct healthcare professional communications for contraceptives containing desogestrel or etonogestrel regarding a small increased risk of men…

Impact analysis · 45/100 · AI-assisted priority

This score prioritizes research; it does not predict an outcome. Method and limitations.

What happened

PRAC agreed direct healthcare professional communications for contraceptives containing desogestrel or etonogestrel regarding a small increased risk of meningioma with prolonged use. PRAC agreed a similar DHPC for the Janus kinase inhibitor Litfulo (ritlecitinib) to strengthen warnings and add a boxed warning. Both recommendations are advisory and will be forwarded to CHMP for centrally authorised products.

Quantitative evidence

Key Numbers
  • One additional meningioma estimated per 67,300 women using desogestrel/etonogestrel over 1 year

Affected entities

desogestrel- or etonogestrel-containing contraceptivesLitfulo (ritlecitinib)

Analysis

The following contextual analysis is AI-assisted and separated from the reported primary-source record above.

Scientific context

The actions address emerging safety signals: intracranial meningioma risk with progestogen contraceptives and class‑wide toxicity of JAK inhibitors applied to Litfulo.

Market context

Contraceptives and Litfulo product information updates may affect prescribing but no specific company is named.

Legal and regulatory context

This is a PRAC recommendation only; the communications will be transmitted to CHMP for endorsement under centrally authorised procedures.

Sources

For informational use only. Verify decisions against the linked regulator or primary source.

Evidence & limits

Source: Open the source record

Record identifier
4eb224bed021aff1fc7caacc2e7615ec7641e5c376ee2e6f54b3aa5950db90cb
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
2026-07-10T130911Z

What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.

Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.

Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.

What this record means · Report an issue with this record